Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dr Sherri McFarland Interview Highlights
View:
Post by GRAMPS1996 on Oct 13, 2022 3:09pm

Dr Sherri McFarland Interview Highlights

A scientist uses photosensitive drugs to treat cancer cells. Dr. McFarland’s PDT approach uses a catheter directly inserted into the bladder.

Also called PDT, the FDA-approved therapy uses drugs activated by light to target and destroy tumor cells.

A chemistry professor at UT Arlington and her team have developed a chemical compound using PDT for certain patients with bladder cancer. Dr. Sherri McFarland explained to KERA’s Sam Baker how PDT works.

Interview highlights were lightly edited for clarity.

INTERVIEW HIGHLIGHTS:

How PDT works

It uses molecules that we call photosensitizers, but I also call them photo drugs. The mechanism involves the molecule, the photosensitizers, the light and oxygen, and when these overlap in space and time, we get the potent anti-cancer effect.

How does the patient receives the chemical compound?

It's most often given by I.V. Our drug is delivered directly to the bladder, so that helps in terms of safety and tolerability.

We wait for the tumors to take up the drug selectively and then we insert a fiber-optic directly into the bladder. The light turns on the otherwise non-toxic anti-cancer agent that we call a photo drug.

And in our case, the drug is selectively taken up by the cancer cells in the bladder. This minimizes any oxide toxicity to healthy tissue in the bladder.

Now, before we bring in our light, we rinse the bladder several times with water to ensure that we've cleared all of the other drug that hasn't gone to cancer cells.

When is PDT used for cancer? 

It’s used in highly specialized cases of esophageal cancer. Some lung cancers. I mean, it's certainly not standard of care for any type of cancer.

Usually, it's used on patients that have already failed other therapies. And in our case for treating bladder cancer, we're doing something similar. These are patients that have become unresponsive to the standard of care — immunotherapy called BCG.

The recommendation at that point is total bladder removal. Some patients are medically unfit to have that procedure. Others just refuse to have the procedure because it's not without its own complications. We try to treat these patients to give them an option so that they don't have to face complete removal of the bladder.

What made you think PDT might work with bladder cancer at that stage?

A few considerations:

  • We certainly needed some strategy that could kill direct cancer cells, but then possibly elicit an immune response that could amplify the effect and is known to have that effect.
  • We can personalize the therapy very easily because we can calculate the dose that's required in terms of the photo drug, as well as the light based on the patient's bladder volume.
  • It's very selective because we can choose where we shine a light. In our case, we illuminate the entire bladder because our filter drug happens to be selective for bladder tumors.

What do you see as the future for photodynamic therapy? 

We're really focused on trying to provide options to cancer patients that have either exhausted all of their other options or there just aren't good options for them.

And so in addition to bladder, we're working in the areas of melanoma, lung glioblastoma, some forms of breast cancer.

Comment by ScienceFirst on Oct 13, 2022 3:32pm
It's a Nov. 2021 interview. https://www.keranews.org/health-wellness/2021-11-29/a-ut-arlington-researcher-is-testing-a-new-option-for-cancer-patients-photodynamic-therapy?_amp=true
Comment by Yoly900 on Oct 13, 2022 3:35pm
This post has been removed in accordance with Community Policy
Comment by Yoly900 on Oct 13, 2022 3:59pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250